Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P21860
UPID:
ERBB3_HUMAN
Alternative names:
Proto-oncogene-like protein c-ErbB-3; Tyrosine kinase-type cell surface receptor HER3
Alternative UPACC:
P21860; A8K6L6; B4DIK7; B4DV32; E9PDT8; Q9BUD7
Background:
Receptor tyrosine-protein kinase erbB-3, also known as Proto-oncogene-like protein c-ErbB-3 and Tyrosine kinase-type cell surface receptor HER3, plays a pivotal role in cell communication and signal transduction. Activated by neuregulins, particularly neuregulin-1 (NRG1), it engages in phosphorylation processes that are crucial for cell differentiation and proliferation.
Therapeutic significance:
The protein's involvement in diseases such as Lethal congenital contracture syndrome 2, Erythroleukemia, familial, and Visceral neuropathy, familial, 1, underscores its potential as a target for therapeutic intervention. Understanding the role of Receptor tyrosine-protein kinase erbB-3 could open doors to potential therapeutic strategies.